Editas Medicine (NASDAQ:EDIT) is a transformative genome editing company founded by a team experienced in genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies. The company is structured around translating its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. Having substantial patent filings and access to other IP covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products, the firm is tackling translating CRISPR/Cas9 and TALENs technologies into a novel class of human therapeutics that enable precise and corrective molecular modification to treat disease at the genetic level. Following a high number of high-profile publications on CRISPR/Cas9 and TALENs, genome editing has emerged as one of the most exciting new areas of scientific research. These advances have made it possible to modify, in a targeted way, almost any gene in the human body with the ability to directly turn on, turn off or edit disease-causing genes.
